52,725 Shares in CeriBell, Inc. $CBLL Purchased by PDT Partners LLC

PDT Partners LLC acquired a new stake in CeriBell, Inc. (NASDAQ:CBLL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 52,725 shares of the company’s stock, valued at approximately $1,026,000. PDT Partners LLC owned about 0.14% of CeriBell as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of CBLL. Caitong International Asset Management Co. Ltd grew its position in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares in the last quarter. Strs Ohio bought a new position in CeriBell during the first quarter worth $27,000. CWM LLC lifted its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period. Finally, Legal & General Group Plc bought a new stake in CeriBell during the second quarter valued at $53,000.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of recent research reports. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. BTIG Research raised their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.

CeriBell Stock Down 2.1%

CBLL stock opened at $23.45 on Thursday. The stock has a market cap of $900.01 million, a PE ratio of -13.32 and a beta of 0.81. The firm’s 50-day simple moving average is $19.89 and its 200 day simple moving average is $19.30. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, sell-side analysts predict that CeriBell, Inc. will post -1.96 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the sale, the insider directly owned 3,765,054 shares in the company, valued at $75,752,886.48. This trade represents a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Michael Taylor sold 13,095 shares of CeriBell stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total value of $306,423.00. Following the sale, the director directly owned 48,478 shares in the company, valued at $1,134,385.20. The trade was a 21.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 382,067 shares of company stock worth $8,025,866. 17.70% of the stock is owned by company insiders.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.